Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
AbbVie IncABBV57.815.3448.8821.4156.41%8.69%55.91$172.76$1,481.2391,911$167.74

Detail of AbbVie Inc

 
CEO
Mr. Robert A. Michael
Employees
50000
Industry
Drug Manufacturers - General
Sector
Healthcare
Market cap
$297B

Company details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$55.53B
Cost of goods (CoG)
-$18.21B
Gross profit (GP)
$37.32B
Operating expense (OE)
-$22.03B
Research and development (R&D)
-$7.94B
General and administrative (G&A)
-$14.09B
Operating income (OI)
$15.29B
Other income expense (OIE)
-$6.16B
Pretax income (PI)
$7.20B
Tax (TAX)
-$2.06B
Net income (NI)
$5.13B
AbbVie Inc
ABBV • XNYS • US
$167.74
+29.03 (20.93%)
Stock vs Industry average
  • Industry average

Dividend yield
3.70%
Trailing annual dividend rate
$6.20
Payout ratio
213.59%
EPS
$2.90
Margin profit
9.22%
52 week low
$138.089996
52 week high
$204.679993
50-day simple moving average
$170.82
200-day simple moving average
$172.76
Percent held by insiders
0.09%
Percent held by institutions
73.46%
Dividend yield
3.09%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ABBV +21.21%
eps change
ABBV -12.64%